Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
COSMIC-311: Cabozantinib versus placebo in patients with radioiodine-refractory ...
Dr Marcia Brose - University of Pennsylvania, Philadelphia, USA
COSMIC-311: Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer ( Dr Marcia Brose - University of Pennsylvania, Philadelphia, USA )
29 Jun 2021
The clinical value of maintenance in multiple myeloma
Prof Wee Joo Chng - National University of Singapore, Singapore
The clinical value of maintenance in multiple myeloma ( Prof Wee Joo Chng  - National University of Singapore, Singapore )
25 Jun 2021
Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-r...
Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA
Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-refractory multiple myeloma patients ( Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA )
25 Jun 2021
Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )
25 Jun 2021
Latest updates in exon 20 insertions focusing on targeted therapies, novel appro...
Dr Mathew Krebs, Dr Santiago Viteri, Dr Shirish Gadgeel and Prof Byoung Chul Cho
Latest updates in exon 20 insertions focusing on targeted therapies, novel approaches, and implications for patients ( Dr Mathew Krebs, Dr Santiago Viteri, Dr Shirish Gadgeel and Prof Byoung Chul Cho )
22 Jun 2021
JAVELIN Bladder 100: Avelumab first-line maintenance plus best supportive care (...
Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA
JAVELIN Bladder 100: Avelumab first-line maintenance plus best supportive care (BSC) versus BSC alone for advanced UC ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )
22 Jun 2021
PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible...
Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA
PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible patients with muscle-invasive bladder cancer ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )
22 Jun 2021
COVID-19 and cancer: Highlights from ASCO 2021
Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA
COVID-19 and cancer: Highlights from ASCO 2021 ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )
22 Jun 2021
Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hod...
Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA
Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma ( Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA )
22 Jun 2021
Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refracto...
Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA
Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma ( Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA )
21 Jun 2021
Clinical research and trials in Romania
Dr Michael Schenker - University of Medicine and Pharmacy Craiova, Center of Onc...
Clinical research and trials in Romania ( Dr Michael Schenker - University of Medicine and Pharmacy Craiova, Center of Oncology Sf Nectarie )
21 Jun 2021
First results of a head-to-head trial of acalabrutinib versus ibrutinib in previ...
Dr John Byrd - The Ohio State University, Columbus, USA
First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukaemia ( Dr John Byrd - The Ohio State University, Columbus, USA )
21 Jun 2021